Global Transcriptomics Market Size Study & Forecast, By Type (Consumables, Instruments, Software, Services) By Technology (Microarrays, q PCR, Sequencing Technology) By Application (Drug Discovery, Diagnostics and Disease Profiling, Others) and Regional A

Global Transcriptomics Market Size Study & Forecast, By Type (Consumables, Instruments, Software, Services) By Technology (Microarrays, q PCR, Sequencing Technology) By Application (Drug Discovery, Diagnostics and Disease Profiling, Others) and Regional Analysis, 2023-2030

Global Transcriptomics Market is valued at approximately USD 6633.20 million in 2022 and is anticipated to grow with a healthy growth rate of more than 7% over the forecast period 2023-2030. Transcriptomics is a branch of molecular biology that deals with the study of the transcriptome, which comprises all the RNA molecules produced in a cell or a population of cells at a specific moment or under specific conditions. It involves the identification, quantification, and analysis of RNA transcripts, including mRNA, non-coding RNA, and small RNA molecules, to understand gene expression patterns and regulatory mechanisms within cells or organisms. The Transcriptomics market is expanding because of factors such as the increasing prevalence of chronic disease and supportive government funding for omics. Transcriptomics provides valuable insights into how genes are transcribed and regulated, as well as their roles in various biological processes, development, diseases, and responses to environmental stimuli. This field often employs high-throughput techniques such as microarrays and next-generation sequencing to capture and analyze RNA expression profiles comprehensively. As a result, the demand for Transcriptomics has progressively increased in the international market during the forecast period 2023-2030.

Transcriptomic analysis helps in identifying potential drug targets and understanding drug responses at the molecular level. With the increasing burden of chronic diseases, pharmaceutical companies are investing in transcriptomic technologies to accelerate drug discovery and development processes. According to the United Nations report, chronic diseases are anticipated to account for 70% of all global fatalities, while the global disease burden will be 56% by the year 2030. The most significant growth is expected in the African and Eastern Mediterranean regions. Transcriptomics is a valuable tool in these research efforts, as it provides insights into gene expression changes associated with disease progression, treatment response, and patient outcomes. Government agencies allocate funds to research institutions and universities to conduct studies in various fields, including Transcriptomics. These grants support basic research, technological advancements, and clinical applications, driving innovation and expanding the capabilities of Transcriptomics technologies. In addition, the National Institutes of Health (NIH) has launched a Multi-Omics for Health and Disease Consortium, backed by an initial funding of approximately USD 11 million. This initiative underscores a concerted effort to propel research in understanding human health through comprehensive multi-omic data analysis. Multi-omics represents a holistic research methodology integrating various ""omics"" data categories including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Each of these data types offers unique insights into different facets of biological systems. Leveraging advancements in high-throughput technologies and data science, the consortium aims to harness the collective power of these diverse data sets to advance our understanding of health and disease. In addition, The Natural Environment Research Council (NERC) in the UK invested USD 88.47 million in a network of seven of their facilities. This investment is designated to support environmental science research by providing access to cutting-edge analytical facilities, field equipment, and expertise, which includes NERC Environmental Omics Facility (NEOF) hosted by the universities of Liverpool and Sheffield, which provides equipment in genomics, bioinformatics, proteomics, and metabolomics support for environmental science researchers. Moreover, the rising demand for personalized medicine and a growing number of next-generation sequencing projects are anticipated to create a lucrative growth opportunity for the market over the forecast period. However, stringent government regulations and the high development cost of Transcriptomics are going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Transcriptomics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing healthcare expenditure in the region. Higher healthcare expenditure often translates into increased funding for biomedical research. This can boost R&D activities in transcriptomics, leading to the development of new technologies, tools, and methodologies for gene expression analysis. The region’s dominant performance is anticipated to propel the overall demand for Transcriptomics. Furthermore, Asia Pacific is expected to grow fastest during the forecast period, owing to factors such as the increasing prevalence of chronic disease in the region. Transcriptomics enables researchers to characterize the transcriptome of individual patients, allowing for personalized diagnosis, prognosis, and treatment selection. With the increasing recognition of the heterogeneity of chronic diseases and the importance of personalized approaches, the demand for transcriptomics technologies in the healthcare industry is expected to grow.

Major market players included in this report are:
Agilent Technologies Inc.
Bio-Rad Laboratories Inc.
F. Hoffmann-La Roche Ltd.
Fluidigm Corporation
General Electric Company
Illuminia Inc.
Merck & Co. Inc.
Promega Corporation
Qiagen N.V.
Thermofisher Scientific Inc.

Recent Developments in the Market:
 In February 2024, NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the commercial availability of the CosMx Human 6K Discovery Panel. The industry's first single-cell spatial panel enables research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), NanoString and independent researchers will demonstrate the attained full transcriptome imaging capability.

Global Transcriptomics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered – Type, Technology, Application, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters to detailed information about the crucial aspects such as driving factors & challenges that will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type
Consumables
Instruments
Software
Services

By Technology
Microarrays
q PCR
Sequencing Technology

By Application
Drug Discovery
Diagnostics and Disease Profiling
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico
RoLA

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.